What the analysis measured
The authors used published group-level weight measurements from six studies of stopping semaglutide or tirzepatide. All six came from a previous systematic review. Their new model combined measurements from different follow-up visits to estimate an average rate across study arms.[1]
The estimated average weight loss at cessation was 15.35 kg (95% credible interval, 11.18 to 19.60 kg). The model estimated regain at 1.04 kg per month (95% credible interval, 0.80 to 1.29). For context on how much weight people regain after stopping, individual withdrawal trials report changes at specific follow-up visits as well as group averages.[1]
What the authors projected
Assuming regain continued at a constant rate, the authors projected that half the initial loss would return in 7.5 months (95% credible interval, 5.05 to 10.57 months). They projected a return to baseline in 15 months (95% credible interval, 10.10 to 21.13 months). The latter point estimate extends beyond the longest observed follow-up of 52 weeks.[1]
What comparisons remain uncertain?
After adjustment, the authors found no clear independent difference in regain rates between semaglutide and tirzepatide. They explored whether behavioral or lifestyle support was associated with slower regain, but the estimate was imprecise. Evidence about continuing at a lower dose comes from a different set of studies because the pooled analysis focused on people who stopped.[1]
If you are considering stopping, discuss follow-up and maintenance options with your prescriber. The study did not test how much weight any additional month of treatment would preserve for an individual.